Related references
Note: Only part of the references are listed.Resistance to HSP90 inhibition involving loss of MCL1 addiction
S. Busacca et al.
ONCOGENE (2016)
Co-operative and Hierarchical Binding of c-FLIP and Caspase-8: A Unified Model Defines How c-FLIP Isoforms Differentially Control Cell Fate
Michelle A. Hughes et al.
MOLECULAR CELL (2016)
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
Andrew W. Roberts et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Cancer Cell-Autonomous TRAIL-R Signaling Promotes KRAS-Driven Cancer Progression, Invasion, and Metastasis
Silvia von Karstedt et al.
CANCER CELL (2015)
Small-Molecule Bcl2 BH4 Antagonist for Lung Cancer Therapy
Bingshe Han et al.
CANCER CELL (2015)
Unexpected hepatotoxicity in a phase I study of TAS266, a novel tetravalent agonistic NanobodyA® targeting the DR5 receptor
Kyriakos P. Papadopoulos et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2015)
BMX Negatively Regulates BAK Function, Thereby Increasing Apoptotic Resistance to Chemotherapeutic Drugs
Joanna L. Fox et al.
CANCER RESEARCH (2015)
Drug-Induced Death Signaling Strategy Rapidly Predicts Cancer Response to Chemotherapy
Joan Montero et al.
CELL (2015)
HSP90 inhibitor NVP-AUY922 enhances TRAIL-induced apoptosis by suppressing the JAK2-STAT3-Mcl-1 signal transduction pathway in colorectal cancer cells
Dae-Hee Lee et al.
CELLULAR SIGNALLING (2015)
Bcl-2 family of proteins as drug targets for cancer chemotherapy: the long way of BH3 mimetics from bench to bedside
Laura Vela et al.
CURRENT OPINION IN PHARMACOLOGY (2015)
Targeting TRAIL in the treatment of cancer: new developments
Bora Lim et al.
EXPERT OPINION ON THERAPEUTIC TARGETS (2015)
Lessons from gain- and loss-of-function models of pro-survival Bcl2 family proteins: implications for targeted therapy
Maja Sochalska et al.
FEBS JOURNAL (2015)
A Phase I Study of the SMAC-Mimetic Birinapant in Adults with Refractory Solid Tumors or Lymphoma
Ravi K. Amaravadi et al.
MOLECULAR CANCER THERAPEUTICS (2015)
Limited Mitochondrial Permeabilization Causes DNA Damage and Genomic Instability in the Absence of Cell Death
Gabriel Ichim et al.
MOLECULAR CELL (2015)
Small molecule Mcl-1 inhibitors for the treatment of cancer
Johannes Belmar et al.
PHARMACOLOGY & THERAPEUTICS (2015)
A set of NF-κB-regulated microRNAs induces acquired TRAIL resistance in Lung cancer
Young-Jun Jeon et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2015)
Potent and selective small-molecule MCL-1 inhibitors demonstrate on-target cancer cell killing activity as single agents and in combination with ABT-263 (navitoclax)
J. D. Leverson et al.
CELL DEATH & DISEASE (2015)
A novel caspase 8 selective small molecule potentiates TRAIL-induced cell death
Octavian Bucur et al.
SCIENTIFIC REPORTS (2015)
Cellular responses to a prolonged delay in mitosis are determined by a DNA damage response controlled by Bcl-2 family proteins
Didier J. Colin et al.
OPEN BIOLOGY (2015)
Acquired mutations in BCL2 family proteins conferring resistance to the BH3 mimetic ABT-199 in lymphoma
Vicente Fresquet et al.
BLOOD (2014)
Smac mimetic promotes glioblastoma cancer stem-like cell differentiation by activating NF-KB
A. Tchoghandjian et al.
CELL DEATH AND DIFFERENTIATION (2014)
Nuclear Death Receptor TRAIL-R2 Inhibits Maturation of Let-7 and Promotes Proliferation of Pancreatic and Other Tumor Cells
Verena Haselmann et al.
GASTROENTEROLOGY (2014)
Phase I Dose-Escalation Study of LCL161, an Oral Inhibitor of Apoptosis Proteins Inhibitor, in Patients With Advanced Solid Tumors
Jeffrey R. Infante et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Phosphorylation of the Proapoptotic BH3-Only Protein Bid Primes Mitochondria for Apoptosis during Mitotic Arrest
Pengbo Wang et al.
CELL REPORTS (2014)
Loss of MCL-1 leads to impaired autophagy and rapid development of heart failure
Robert L. Thomas et al.
GENES & DEVELOPMENT (2013)
Autophagy contributes to modulating the cytotoxicities of Bcl-2 homology domain-3 mimetics
Le Yu et al.
SEMINARS IN CANCER BIOLOGY (2013)
Sensitization of melanoma cells for TRAIL-induced apoptosis by BMS-345541 correlates with altered phosphorylation and activation of Bax
A. Berger et al.
CELL DEATH & DISEASE (2013)
Identification of non-canonical NF-κB signaling as a critical mediator of Smac mimetic-stimulated migration and invasion of glioblastoma cells
A. Tchoghandjian et al.
CELL DEATH & DISEASE (2013)
Sabutoclax (BI97C1) and BI112D1, Putative Inhibitors of MCL-1, Induce Mitochondrial Fragmentation Either Upstream of or Independent of Apoptosis
Shankar Varadarajan et al.
NEOPLASIA (2013)
Relative Mitochondrial Priming of Myeloblasts and Normal HSCs Determines Chemotherapeutic Success in AML
Thanh-Trang Vo et al.
CELL (2012)
Glucose-a sweet way to die Metabolic switching modulates tumor cell death
Marion MacFarlane et al.
CELL CYCLE (2012)
The 'complexities' of life and death: Death receptor signalling platforms
Laura S. Dickens et al.
EXPERIMENTAL CELL RESEARCH (2012)
A Death Effector Domain Chain DISC Model Reveals a Crucial Role for Caspase-8 Chain Assembly in Mediating Apoptotic Cell Death
Laura S. Dickens et al.
MOLECULAR CELL (2012)
Glycolysis inhibition targets Mcl-1 to restore sensitivity of lymphoma cells to ABT-737-induced apoptosis
O. Meynet et al.
LEUKEMIA (2012)
Anti-apoptotic MCL-1 localizes to the mitochondrial matrix and couples mitochondrial fusion to respiration
Rhonda M. Perciavalle et al.
NATURE CELL BIOLOGY (2012)
Switching from aerobic glycolysis to oxidative phosphorylation modulates the sensitivity of mantle cell lymphoma cells to TRAIL
G. L. Robinson et al.
ONCOGENE (2012)
Navitoclax (ABT-263) Accelerates Apoptosis during Drug-Induced Mitotic Arrest by Antagonizing Bcl-xL
Jue Shi et al.
CANCER RESEARCH (2011)
Hallmarks of Cancer: The Next Generation
Douglas Hanahan et al.
CELL (2011)
Pretreatment Mitochondrial Priming Correlates with Clinical Response to Cytotoxic Chemotherapy
Triona Ni Chonghaile et al.
SCIENCE (2011)
Tyrosine dephosphorylation is required for Bak activation in apoptosis
Joanna L. Fox et al.
EMBO JOURNAL (2010)
TRAIL treatment provokes mutations in surviving cells
M. M. Lovric et al.
ONCOGENE (2010)
Reconstitution of the Death-inducing Signaling Comp ex Reveals a Substrate Switch that Determines CD95-Mediated Death or Survival
Michelle A. Hughes et al.
MOLECULAR CELL (2009)
IAP antagonists induce autoubiquitination of c-IAPs, NF-κB activation, and TNFα-dependent apoptosis
Eugene Varfolomeev et al.
CELL (2007)
IAP antagonists target cIAP1 to induce TNFα- dependent apoptosis
James E. Vince et al.
CELL (2007)
Increased hepatotoxicity of tumor necrosis factor-related apoptosis-inducing ligand in diseased human liver
Xandra Volkmann et al.
HEPATOLOGY (2007)
Autocrine TNFα signaling renders human cancer cells susceptible to smac-mimetic-induced apoptosis
Sean L. Petersen et al.
CANCER CELL (2007)
Barriers to effective TRAIL-targeted therapy of malignancy
Martin J. S. Dyer et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Preclinical differentiation between apparently safe and potentially hepatotoxic applications of TRAIL either alone or in combination with chemotherapeutic drugs
TM Ganten et al.
CLINICAL CANCER RESEARCH (2006)
TRAIL receptor-selective mutants signal to apoptosis via TRAIL-R1 in primary lymphoid malignancies
M MacFarlane et al.
CANCER RESEARCH (2005)
Somatic mutations of TRAIL-receptor 1 and TRAIL-receptor 2 genes in non-Hodgkin's lymphoma
SH Lee et al.
ONCOGENE (2001)
Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand
M Jo et al.
NATURE MEDICINE (2000)
Share Paper
